Skip to content

Study Where Healthy Volunteers Evaluate LoFric Catheters

A Randomized, Single-blind, Cross-over, Single Centre Study in Healthy Volunteers Evaluating Subject Perception of Urinary Catheters Manufactured in a New Process With New Solvent

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00802750
Enrollment
25
Registered
2008-12-05
Start date
2008-11-30
Completion date
2008-12-31
Last updated
2021-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheterization

Brief summary

The purpose of this study is to evaluate healthy volunteers perception of catheterization with LoFric catheters with new solvents in the manufacturing process. The subjects will be catheterized three times during one visit day. The hypothesis is that the subjects' perception of catheterization is the same when using the test catheters compared to the reference catheter.

Interventions

DEVICELoFric POBE

LoFric POBE, Nelaton 40 cm, CH 12 with new solvent. Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters.

Sponsors

Wellspect HealthCare
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Provision of written informed consent * Healthy volunteers * Males age 18 years and over

Exclusion criteria

* Known or suspected, current impairment of and/or decreased urethral sensibility * History of urethral disease * History of urinary tract infection within three months, or ongoing symptomatic urinary tract infection * Use of medications that may affect the urethra's dryness (e. g. anti-cholinergic drugs or cortisone) * Current drug, alcohol or other substance abuse * Other significant disease or condition (e.g. benign prostate hypertrophy, other prostatic lesions), which may interfere with treatment and/or evaluation * Allergy to Trimethoprim * Suspected poor compliance with the protocol during the complete study period.

Design outcomes

Primary

MeasureTime frame
Healthy volunteers perception of catheterizationAt each catheterization (three times during one day)

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026